四环医药控股
Sihuan Pharmaceutical Holdings
业务简介
四环医药控股是一家领先的医药公司，就市场份额而言，心脑血管药物业务居中国之首。集团拥有别具一格的销售及市场推广模式，由逾2,000名分销商组成的庞大的全国性分销网络提供支持，该网络覆盖全国31个省市及自治区近10,000家医院。
集团的研发实力雄厚，侧重於发展创新及首次进入市场的仿制药，并拥有物色、获得及开发市场领先药物的往绩记录。集团供应14种心脑血管药物组合，用作治疗多种心脑血管疾病，销量最高的为心脑血管药物克林澳、安捷利及川青，合共约占中国脑血管及周边血管扩张治疗市场的17.1%，脑血管及周边血管扩张治疗市场是最大的心脑血管药物细分市场。
集团亦与心脑血管药物一起推广及销售30种抗感染药物及其他药物的多样化组合。集团现时推广及销售的所有药物均为处方药。
Thursday, October 28, 2010
Thursday, October 14, 2010
CVTM (893, $3.43) 6M Target $4.10 BUY
CHINAVTM MINING 00893 14/10/2010
Action Buy
Target Price $4.100
Reason
CVTM (893, $3.43) 6M Target $4.10 BUY
Event: A good timing to accumulate CVTM.
CVTM's share price has corrected 33% year-to-date and is still slightly below its IPO price of $3.50 in October 2009 amid the downturn of downstream steel industry starting in 2Q10. Given the company’s high earnings visibility, low production cost and strong earnings growth, we believe the stock is undervalued. Current level provides investors a good entry opportunity, in our view.
As the second largest iron ore producer in Sichuan area and the only major listed PRC iron ore player in Hong Kong, CVTM is the a beneficiary of the 'Great Western Development Plan' and robust demand from steel mills in Sichuan. Post-earthquake reconstruction and urbanization in Sichuan have been the driving force of steel demand in the region. According to company guidance, there will be approximately 10.1mnt of new crude steel production capacity in Sichuan area by 2012, up 66% from 2009 level. This in turn will drive demand of iron ore and support iron ore price in the area as it is costly to transport iron ore from coastal areas to inland.
Company recorded a 41% and 75% yoy growth in revenue and net profit to RMB 686mn and RMB 234mn respectively in 1H10. Gross margin expanded largely from 43.1% in 1H09 to 52.4% in 1H10 thanks to 1) increase in ASP which outpaced the surge of average unit cost and 2) increase in sales volume of iron concentrates and pellets by 9% and 13% respectively.
Iron concentrates output was up 16% yoy in 1H10 to 866kt, which only accounted for around 44% of company's full year target. This was mainly due to the drought in Sichuan which has interrupted the water and power supplies earlier this year. As company has commenced iron concentrates production in two new processing facilities in 1H10, it is highly likely that company can achieve its full year target of 1.95mnt of iron concentrates.
Realized ASP of iron concentrate and pellets in 1H10 were RMB 665/t and RMB 880/t, up 29% and 21% yoy respectively and were 9% and 1% above the floor contract price they signed with their customers. Even though domestic iron ore price may face short-term pressure amid the recent steel production cut to meet provinces' energy reduction target, we believe earnings risk of CVTM remains low as it has already signed sales agreement with its major customers for 2010 with floor contract price.
Meanwhile, company has continued to expand its capacity through acquisition of two processing plants and two iron ore mining rights in the area. While the iron ore mines it acquired are still at exploration stages, the two processing plants it acquired have lifted its production capacity of iron concentrates from 1.2mnt to 2.3mnt in 1H10. With another iron concentrate production line being completed by September 2010, its iron concentrates capacity can reach 2.6mnt by year-end. It is also constructing a new pellet production line that will lift its pellet production capacity from current level of 360kt to 1,360kt by 2H11.
Assuming that CVTM will sell its products at contract floor price in 2H10 and achieving its full-year production target, we estimate that company will earn RMB 501mn (EPS RMB 0.24) in 2010. Meanwhile, assuming that 1) ASP of iron concentrates and iron pellets up 9% and 3% respectively; 2) production capacity up by 23% and 3) production cost increases by 3% in 2011, we estimate it will record a net profit of RMB 685mn (EPS RMB 0.33) in 2011, implying a EPS CAGR of 28% between 2009 and 2011.
CVTM is trading at 12.3x 2010 PER and 8.9x 2011 PER that we think is undervalued given its high earnings momentum, strong organic growth and potential acquisition pipeline.
We rate it a BUY with a 6-month target price of $4.10, implying an 11x 2011 PER. Key downside risks are production disruption due to natural disasters or dispute with its mining contractor and lower than expected steel demand in Sichuan region.
Action Buy
Target Price $4.100
Reason
CVTM (893, $3.43) 6M Target $4.10 BUY
Event: A good timing to accumulate CVTM.
CVTM's share price has corrected 33% year-to-date and is still slightly below its IPO price of $3.50 in October 2009 amid the downturn of downstream steel industry starting in 2Q10. Given the company’s high earnings visibility, low production cost and strong earnings growth, we believe the stock is undervalued. Current level provides investors a good entry opportunity, in our view.
As the second largest iron ore producer in Sichuan area and the only major listed PRC iron ore player in Hong Kong, CVTM is the a beneficiary of the 'Great Western Development Plan' and robust demand from steel mills in Sichuan. Post-earthquake reconstruction and urbanization in Sichuan have been the driving force of steel demand in the region. According to company guidance, there will be approximately 10.1mnt of new crude steel production capacity in Sichuan area by 2012, up 66% from 2009 level. This in turn will drive demand of iron ore and support iron ore price in the area as it is costly to transport iron ore from coastal areas to inland.
Company recorded a 41% and 75% yoy growth in revenue and net profit to RMB 686mn and RMB 234mn respectively in 1H10. Gross margin expanded largely from 43.1% in 1H09 to 52.4% in 1H10 thanks to 1) increase in ASP which outpaced the surge of average unit cost and 2) increase in sales volume of iron concentrates and pellets by 9% and 13% respectively.
Iron concentrates output was up 16% yoy in 1H10 to 866kt, which only accounted for around 44% of company's full year target. This was mainly due to the drought in Sichuan which has interrupted the water and power supplies earlier this year. As company has commenced iron concentrates production in two new processing facilities in 1H10, it is highly likely that company can achieve its full year target of 1.95mnt of iron concentrates.
Realized ASP of iron concentrate and pellets in 1H10 were RMB 665/t and RMB 880/t, up 29% and 21% yoy respectively and were 9% and 1% above the floor contract price they signed with their customers. Even though domestic iron ore price may face short-term pressure amid the recent steel production cut to meet provinces' energy reduction target, we believe earnings risk of CVTM remains low as it has already signed sales agreement with its major customers for 2010 with floor contract price.
Meanwhile, company has continued to expand its capacity through acquisition of two processing plants and two iron ore mining rights in the area. While the iron ore mines it acquired are still at exploration stages, the two processing plants it acquired have lifted its production capacity of iron concentrates from 1.2mnt to 2.3mnt in 1H10. With another iron concentrate production line being completed by September 2010, its iron concentrates capacity can reach 2.6mnt by year-end. It is also constructing a new pellet production line that will lift its pellet production capacity from current level of 360kt to 1,360kt by 2H11.
Assuming that CVTM will sell its products at contract floor price in 2H10 and achieving its full-year production target, we estimate that company will earn RMB 501mn (EPS RMB 0.24) in 2010. Meanwhile, assuming that 1) ASP of iron concentrates and iron pellets up 9% and 3% respectively; 2) production capacity up by 23% and 3) production cost increases by 3% in 2011, we estimate it will record a net profit of RMB 685mn (EPS RMB 0.33) in 2011, implying a EPS CAGR of 28% between 2009 and 2011.
CVTM is trading at 12.3x 2010 PER and 8.9x 2011 PER that we think is undervalued given its high earnings momentum, strong organic growth and potential acquisition pipeline.
We rate it a BUY with a 6-month target price of $4.10, implying an 11x 2011 PER. Key downside risks are production disruption due to natural disasters or dispute with its mining contractor and lower than expected steel demand in Sichuan region.
Subscribe to:
Posts (Atom)